passiflora incarnata + valeriana officinalis + crataegus oxyacantha

This phytotherapeutic product, often referred to by the study code **CPV**, is a fixed-dose combination of dry extracts from three plants: *Passiflora incarnata* (passionflower), *Valeriana officinalis* (valerian), and *Crataegus oxyacantha* (hawthorn). Developed and marketed by the Brazilian pharmaceutical company **EMS S/A** under the brand name **Sominex**, the formulation typically contains 50 mg of *Passiflora incarnata*, 40 mg of *Valeriana officinalis*, and 30 mg of *Crataegus oxyacantha*. The product is primarily indicated for the treatment of anxiety disorders and psychophysiological insomnia. Its mechanism of action involves the modulation of GABAergic pathways in the central nervous system, where the active constituents (such as valerenic acid and flavonoids) act as positive allosteric modulators of GABA-A receptors, resulting in anxiolytic and sedative effects. The combination has been evaluated in clinical trials for efficacy and safety, demonstrating a profile suitable for managing mild to moderate sleep and anxiety disturbances.

Brand names

Sominex

Other names

passionflower + valerian + hawthorn